nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Carboplatin—bone cancer	0.167	0.303	CbGbCtD
Leflunomide—ABCG2—Cisplatin—bone cancer	0.143	0.259	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—bone cancer	0.0956	0.174	CbGbCtD
Leflunomide—ABCG2—Methotrexate—bone cancer	0.0926	0.168	CbGbCtD
Leflunomide—CYP2C9—Cisplatin—bone cancer	0.053	0.0962	CbGbCtD
Leflunomide—DHODH—Pyrimidine metabolism—NT5C3A—bone cancer	0.0328	0.189	CbGpPWpGaD
Leflunomide—DHODH—Nucleotide metabolism—NT5C3A—bone cancer	0.0128	0.0735	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.007	0.0402	CbGpPWpGaD
Leflunomide—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00576	0.0331	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00427	0.0245	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00412	0.0237	CbGpPWpGaD
Leflunomide—Niflumic Acid—PTGS2—bone cancer	0.00297	1	CrCbGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—RGS1—bone cancer	0.00285	0.0164	CbGpPWpGaD
Leflunomide—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.00281	0.0162	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL3—bone cancer	0.0023	0.0132	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.0023	0.0132	CbGpPWpGaD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00221	0.0127	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00212	0.0122	CbGpPWpGaD
Leflunomide—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00212	0.0122	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—PLAU—bone cancer	0.0021	0.0121	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—GNA11—bone cancer	0.002	0.0115	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—GNA11—bone cancer	0.00198	0.0114	CbGpPWpGaD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00189	0.0109	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00189	0.0108	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—MET—bone cancer	0.00185	0.0106	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.0017	0.00978	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00169	0.0097	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.00167	0.00961	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—MMP2—bone cancer	0.00166	0.00953	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00162	0.00933	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—TGFBR2—bone cancer	0.00155	0.00893	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—IGF1R—bone cancer	0.00146	0.00841	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—GNA11—bone cancer	0.00144	0.0083	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—EZH2—bone cancer	0.00144	0.00826	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00141	0.00809	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NDUFA12—bone cancer	0.0014	0.00806	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.00138	0.00791	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—PLAU—bone cancer	0.00135	0.00775	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00134	0.00769	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00134	0.00769	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—JUN—bone cancer	0.00128	0.00736	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MET—bone cancer	0.00127	0.00733	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—MMP9—bone cancer	0.00125	0.00716	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0012	0.00688	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—JUN—bone cancer	0.00119	0.00684	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—EIF2S1—bone cancer	0.00119	0.00682	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL3—bone cancer	0.00118	0.00679	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NT5C3A—bone cancer	0.00116	0.00668	CbGpPWpGaD
Leflunomide—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00109	0.00627	CbGpPWpGaD
Leflunomide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00107	0.00614	CbGpPWpGaD
Leflunomide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00103	0.00591	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00102	0.00588	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.00102	0.00586	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—JUN—bone cancer	0.001	0.00577	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—RB1—bone cancer	0.001	0.00575	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000994	0.00571	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000953	0.00548	CbGpPWpGaD
Leflunomide—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000952	0.00547	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—bone cancer	0.000938	0.00539	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—MMP2—bone cancer	0.000928	0.00533	CbGpPWpGaD
Leflunomide—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000913	0.00525	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000903	0.00519	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000887	0.0051	CbGpPWpGaD
Leflunomide—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000878	0.00505	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—ATF1—bone cancer	0.000876	0.00503	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—JUN—bone cancer	0.000821	0.00472	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—JUN—bone cancer	0.000821	0.00472	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000814	0.00468	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—CDK4—bone cancer	0.000812	0.00466	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MMP9—bone cancer	0.000799	0.00459	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000756	0.00435	CbGpPWpGaD
Leflunomide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000734	0.00422	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—JUN—bone cancer	0.000726	0.00417	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—JUN—bone cancer	0.000717	0.00412	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000699	0.00402	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—MMP9—bone cancer	0.000698	0.00401	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000657	0.00378	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000603	0.00347	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000597	0.00343	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—EGFR—bone cancer	0.000564	0.00324	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—MMP9—bone cancer	0.000561	0.00323	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL3—bone cancer	0.000551	0.00317	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—JUN—bone cancer	0.000546	0.00314	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—JUN—bone cancer	0.000523	0.00301	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000517	0.00297	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000515	0.00296	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ENO2—bone cancer	0.000509	0.00292	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—DHFR—bone cancer	0.000472	0.00271	CbGpPWpGaD
Leflunomide—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000469	0.0027	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—BRAF—bone cancer	0.000468	0.00269	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—bone cancer	0.000468	0.00269	CbGpPWpGaD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000444	0.00255	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GNA11—bone cancer	0.000441	0.00254	CbGpPWpGaD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000438	0.00252	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000434	0.00249	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CYP3A4—bone cancer	0.0004	0.0023	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000379	0.00218	CbGpPWpGaD
Leflunomide—Agranulocytosis—Methotrexate—bone cancer	0.000377	0.00139	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000375	0.00138	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—JUN—bone cancer	0.000375	0.00215	CbGpPWpGaD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000374	0.00215	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000374	0.00215	CbGpPWpGaD
Leflunomide—Pancytopenia—Doxorubicin—bone cancer	0.000373	0.00137	CcSEcCtD
Leflunomide—Renal failure—Epirubicin—bone cancer	0.000372	0.00137	CcSEcCtD
Leflunomide—Body temperature increased—Cisplatin—bone cancer	0.000372	0.00136	CcSEcCtD
Leflunomide—Neuropathy peripheral—Epirubicin—bone cancer	0.000371	0.00136	CcSEcCtD
Leflunomide—Stomatitis—Epirubicin—bone cancer	0.000369	0.00135	CcSEcCtD
Leflunomide—Jaundice—Epirubicin—bone cancer	0.000369	0.00135	CcSEcCtD
Leflunomide—Urinary tract infection—Epirubicin—bone cancer	0.000368	0.00135	CcSEcCtD
Leflunomide—Conjunctivitis—Epirubicin—bone cancer	0.000368	0.00135	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—bone cancer	0.000367	0.00135	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—bone cancer	0.000367	0.00135	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000365	0.00134	CcSEcCtD
Leflunomide—Haemoglobin—Methotrexate—bone cancer	0.000365	0.00134	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—bone cancer	0.000363	0.00133	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—bone cancer	0.000363	0.00133	CcSEcCtD
Leflunomide—Pollakiuria—Doxorubicin—bone cancer	0.000363	0.00133	CcSEcCtD
Leflunomide—Haematuria—Epirubicin—bone cancer	0.000361	0.00132	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—bone cancer	0.00036	0.00132	CcSEcCtD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00036	0.00207	CbGpPWpGaD
Leflunomide—Urinary tract disorder—Methotrexate—bone cancer	0.000359	0.00132	CcSEcCtD
Leflunomide—Hepatobiliary disease—Epirubicin—bone cancer	0.000358	0.00131	CcSEcCtD
Leflunomide—Epistaxis—Epirubicin—bone cancer	0.000357	0.00131	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—bone cancer	0.000356	0.00131	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—bone cancer	0.000355	0.0013	CcSEcCtD
Leflunomide—Sinusitis—Epirubicin—bone cancer	0.000355	0.0013	CcSEcCtD
Leflunomide—Hyperglycaemia—Doxorubicin—bone cancer	0.000354	0.0013	CcSEcCtD
Leflunomide—Agranulocytosis—Epirubicin—bone cancer	0.000353	0.0013	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—bone cancer	0.000352	0.00129	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—bone cancer	0.00035	0.00129	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—bone cancer	0.00035	0.00129	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000347	0.00127	CcSEcCtD
Leflunomide—Hypersensitivity—Cisplatin—bone cancer	0.000346	0.00127	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—TP53—bone cancer	0.000345	0.00198	CbGpPWpGaD
Leflunomide—Renal failure—Doxorubicin—bone cancer	0.000344	0.00126	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—bone cancer	0.000343	0.00126	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—bone cancer	0.000343	0.00126	CcSEcCtD
Leflunomide—DHODH—Metabolism—GSTP1—bone cancer	0.000342	0.00197	CbGpPWpGaD
Leflunomide—Haemoglobin—Epirubicin—bone cancer	0.000342	0.00125	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—bone cancer	0.000341	0.00125	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—bone cancer	0.000341	0.00125	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—JUN—bone cancer	0.000341	0.00196	CbGpPWpGaD
Leflunomide—Rhinitis—Epirubicin—bone cancer	0.000341	0.00125	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—bone cancer	0.00034	0.00125	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—bone cancer	0.00034	0.00125	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—bone cancer	0.00034	0.00125	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—bone cancer	0.00034	0.00125	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—bone cancer	0.000339	0.00125	CcSEcCtD
Leflunomide—Asthenia—Cisplatin—bone cancer	0.000337	0.00124	CcSEcCtD
Leflunomide—Pharyngitis—Epirubicin—bone cancer	0.000337	0.00124	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—bone cancer	0.000337	0.00124	CcSEcCtD
Leflunomide—Urinary tract disorder—Epirubicin—bone cancer	0.000336	0.00123	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—bone cancer	0.000335	0.00123	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—bone cancer	0.000334	0.00123	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—bone cancer	0.000334	0.00123	CcSEcCtD
Leflunomide—Urethral disorder—Epirubicin—bone cancer	0.000333	0.00122	CcSEcCtD
Leflunomide—Hepatobiliary disease—Doxorubicin—bone cancer	0.000331	0.00122	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—bone cancer	0.00033	0.00121	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—bone cancer	0.000329	0.00121	CcSEcCtD
Leflunomide—Immune system disorder—Methotrexate—bone cancer	0.000328	0.0012	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—bone cancer	0.000327	0.0012	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—bone cancer	0.000327	0.0012	CcSEcCtD
Leflunomide—Chills—Methotrexate—bone cancer	0.000326	0.0012	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000325	0.00187	CbGpPWpGaD
Leflunomide—Diarrhoea—Cisplatin—bone cancer	0.000322	0.00118	CcSEcCtD
Leflunomide—Erythema multiforme—Epirubicin—bone cancer	0.000321	0.00118	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—bone cancer	0.000321	0.00118	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—bone cancer	0.000318	0.00117	CcSEcCtD
Leflunomide—Eye disorder—Epirubicin—bone cancer	0.000318	0.00117	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—bone cancer	0.000316	0.00116	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—bone cancer	0.000316	0.00116	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—bone cancer	0.000315	0.00116	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—bone cancer	0.000315	0.00116	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—bone cancer	0.000314	0.00115	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—bone cancer	0.000314	0.00115	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—bone cancer	0.000312	0.00115	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—bone cancer	0.000311	0.00114	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—bone cancer	0.00031	0.00114	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—bone cancer	0.00031	0.00114	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—bone cancer	0.000309	0.00113	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—bone cancer	0.000308	0.00113	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000307	0.00177	CbGpPWpGaD
Leflunomide—Immune system disorder—Epirubicin—bone cancer	0.000307	0.00113	CcSEcCtD
Leflunomide—Mediastinal disorder—Epirubicin—bone cancer	0.000306	0.00112	CcSEcCtD
Leflunomide—Back pain—Methotrexate—bone cancer	0.000306	0.00112	CcSEcCtD
Leflunomide—Chills—Epirubicin—bone cancer	0.000305	0.00112	CcSEcCtD
Leflunomide—Arrhythmia—Epirubicin—bone cancer	0.000304	0.00111	CcSEcCtD
Leflunomide—Alopecia—Epirubicin—bone cancer	0.0003	0.0011	CcSEcCtD
Leflunomide—Vomiting—Cisplatin—bone cancer	0.000299	0.0011	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—bone cancer	0.000298	0.00109	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—bone cancer	0.000298	0.00109	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—bone cancer	0.000297	0.00109	CcSEcCtD
Leflunomide—Rash—Cisplatin—bone cancer	0.000296	0.00109	CcSEcCtD
Leflunomide—Dermatitis—Cisplatin—bone cancer	0.000296	0.00109	CcSEcCtD
Leflunomide—Malnutrition—Epirubicin—bone cancer	0.000296	0.00109	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—bone cancer	0.000294	0.00108	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—bone cancer	0.000293	0.00108	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—bone cancer	0.000292	0.00107	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—bone cancer	0.000292	0.00107	CcSEcCtD
Leflunomide—Flatulence—Epirubicin—bone cancer	0.000291	0.00107	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00029	0.00167	CbGpPWpGaD
Leflunomide—Dysgeusia—Epirubicin—bone cancer	0.00029	0.00106	CcSEcCtD
Leflunomide—Back pain—Epirubicin—bone cancer	0.000286	0.00105	CcSEcCtD
Leflunomide—Malaise—Methotrexate—bone cancer	0.000285	0.00105	CcSEcCtD
Leflunomide—Muscle spasms—Epirubicin—bone cancer	0.000284	0.00104	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—bone cancer	0.000284	0.00104	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—bone cancer	0.000284	0.00104	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—bone cancer	0.000283	0.00104	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—bone cancer	0.000283	0.00104	CcSEcCtD
Leflunomide—Chills—Doxorubicin—bone cancer	0.000282	0.00104	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—bone cancer	0.000281	0.00103	CcSEcCtD
Leflunomide—Nausea—Cisplatin—bone cancer	0.000279	0.00102	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—bone cancer	0.000279	0.00102	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—bone cancer	0.000278	0.00102	CcSEcCtD
Leflunomide—Cough—Methotrexate—bone cancer	0.000276	0.00101	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—bone cancer	0.000275	0.00101	CcSEcCtD
Leflunomide—Ill-defined disorder—Epirubicin—bone cancer	0.000274	0.00101	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—bone cancer	0.000274	0.001	CcSEcCtD
Leflunomide—Anaemia—Epirubicin—bone cancer	0.000273	0.001	CcSEcCtD
Leflunomide—Flatulence—Doxorubicin—bone cancer	0.00027	0.00099	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—bone cancer	0.000269	0.000988	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—bone cancer	0.000269	0.000988	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—bone cancer	0.000269	0.000988	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—bone cancer	0.000268	0.00154	CbGpPWpGaD
Leflunomide—Dysgeusia—Doxorubicin—bone cancer	0.000268	0.000984	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000267	0.000981	CcSEcCtD
Leflunomide—Malaise—Epirubicin—bone cancer	0.000267	0.000979	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—bone cancer	0.000266	0.000976	CcSEcCtD
Leflunomide—Vertigo—Epirubicin—bone cancer	0.000266	0.000976	CcSEcCtD
Leflunomide—Leukopenia—Epirubicin—bone cancer	0.000265	0.000972	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—bone cancer	0.000265	0.000972	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—bone cancer	0.000263	0.000966	CcSEcCtD
Leflunomide—Palpitations—Epirubicin—bone cancer	0.000261	0.00096	CcSEcCtD
Leflunomide—Cough—Epirubicin—bone cancer	0.000258	0.000947	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—bone cancer	0.000258	0.000947	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—bone cancer	0.000258	0.000947	CcSEcCtD
Leflunomide—Infection—Methotrexate—bone cancer	0.000256	0.000941	CcSEcCtD
Leflunomide—Hypertension—Epirubicin—bone cancer	0.000255	0.000937	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—bone cancer	0.000254	0.000932	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—bone cancer	0.000253	0.000929	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—bone cancer	0.000253	0.000929	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000253	0.00145	CbGpPWpGaD
Leflunomide—Thrombocytopenia—Methotrexate—bone cancer	0.000253	0.000927	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—bone cancer	0.000252	0.000924	CcSEcCtD
Leflunomide—Myalgia—Epirubicin—bone cancer	0.000252	0.000924	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—bone cancer	0.000252	0.000924	CcSEcCtD
Leflunomide—Anxiety—Epirubicin—bone cancer	0.000251	0.000921	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—bone cancer	0.000251	0.00092	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00025	0.00144	CbGpPWpGaD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00025	0.000918	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—bone cancer	0.000249	0.000915	CcSEcCtD
Leflunomide—Discomfort—Epirubicin—bone cancer	0.000249	0.000913	CcSEcCtD
Leflunomide—Malaise—Doxorubicin—bone cancer	0.000247	0.000906	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—bone cancer	0.000246	0.000904	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—bone cancer	0.000246	0.000903	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—bone cancer	0.000246	0.000903	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—bone cancer	0.000245	0.000899	CcSEcCtD
Leflunomide—Palpitations—Doxorubicin—bone cancer	0.000242	0.000888	CcSEcCtD
Leflunomide—Anaphylactic shock—Epirubicin—bone cancer	0.000241	0.000886	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—bone cancer	0.000241	0.000885	CcSEcCtD
Leflunomide—Infection—Epirubicin—bone cancer	0.00024	0.00088	CcSEcCtD
Leflunomide—Cough—Doxorubicin—bone cancer	0.000239	0.000877	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000239	0.00137	CbGpPWpGaD
Leflunomide—Nervous system disorder—Epirubicin—bone cancer	0.000237	0.000869	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—bone cancer	0.000236	0.000868	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—bone cancer	0.000236	0.000867	CcSEcCtD
Leflunomide—Tachycardia—Epirubicin—bone cancer	0.000236	0.000865	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000235	0.000863	CcSEcCtD
Leflunomide—Skin disorder—Epirubicin—bone cancer	0.000235	0.000861	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—bone cancer	0.000233	0.000857	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—bone cancer	0.000233	0.000856	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—bone cancer	0.000233	0.000855	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—bone cancer	0.000233	0.000855	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—bone cancer	0.000233	0.000855	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—bone cancer	0.000232	0.000852	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—bone cancer	0.000232	0.00085	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000231	0.000849	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—bone cancer	0.00023	0.000845	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—bone cancer	0.00023	0.000845	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—bone cancer	0.00023	0.000844	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—RGS1—bone cancer	0.00023	0.00132	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GRM4—bone cancer	0.00023	0.00132	CbGpPWpGaD
Leflunomide—Dry mouth—Doxorubicin—bone cancer	0.000228	0.000837	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000228	0.00131	CbGpPWpGaD
Leflunomide—Dyspepsia—Methotrexate—bone cancer	0.000227	0.000834	CcSEcCtD
Leflunomide—ABCG2—Metabolism—NDUFA12—bone cancer	0.000227	0.0013	CbGpPWpGaD
Leflunomide—Hypotension—Epirubicin—bone cancer	0.000226	0.000828	CcSEcCtD
Leflunomide—Decreased appetite—Methotrexate—bone cancer	0.000224	0.000823	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—bone cancer	0.000223	0.00082	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000223	0.000818	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—bone cancer	0.000222	0.000816	CcSEcCtD
Leflunomide—Infection—Doxorubicin—bone cancer	0.000222	0.000815	CcSEcCtD
Leflunomide—Pain—Methotrexate—bone cancer	0.000221	0.00081	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00022	0.000807	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—bone cancer	0.000219	0.000804	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—bone cancer	0.000219	0.000803	CcSEcCtD
Leflunomide—Insomnia—Epirubicin—bone cancer	0.000218	0.000801	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—bone cancer	0.000218	0.0008	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—bone cancer	0.000217	0.000796	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—bone cancer	0.000217	0.000796	CcSEcCtD
Leflunomide—Hyperhidrosis—Doxorubicin—bone cancer	0.000216	0.000793	CcSEcCtD
Leflunomide—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000216	0.00124	CbGpPWpGaD
Leflunomide—Dyspnoea—Epirubicin—bone cancer	0.000215	0.00079	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—bone cancer	0.000213	0.000782	CcSEcCtD
Leflunomide—Feeling abnormal—Methotrexate—bone cancer	0.000213	0.00078	CcSEcCtD
Leflunomide—Dyspepsia—Epirubicin—bone cancer	0.000213	0.00078	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—bone cancer	0.000211	0.000774	CcSEcCtD
Leflunomide—Decreased appetite—Epirubicin—bone cancer	0.00021	0.00077	CcSEcCtD
Leflunomide—Hypotension—Doxorubicin—bone cancer	0.000209	0.000766	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000208	0.000765	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—bone cancer	0.000208	0.000764	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000208	0.00119	CbGpPWpGaD
Leflunomide—Constipation—Epirubicin—bone cancer	0.000206	0.000758	CcSEcCtD
Leflunomide—Pain—Epirubicin—bone cancer	0.000206	0.000758	CcSEcCtD
Leflunomide—Urticaria—Methotrexate—bone cancer	0.000205	0.000752	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—bone cancer	0.000204	0.000749	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—bone cancer	0.000204	0.000749	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000204	0.000747	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—bone cancer	0.000202	0.000742	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—bone cancer	0.000201	0.000736	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GRM1—bone cancer	0.000199	0.00114	CbGpPWpGaD
Leflunomide—Dyspnoea—Doxorubicin—bone cancer	0.000199	0.000731	CcSEcCtD
Leflunomide—Feeling abnormal—Epirubicin—bone cancer	0.000199	0.00073	CcSEcCtD
Leflunomide—Gastrointestinal pain—Epirubicin—bone cancer	0.000197	0.000725	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—bone cancer	0.000197	0.000722	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000194	0.00112	CbGpPWpGaD
Leflunomide—Decreased appetite—Doxorubicin—bone cancer	0.000194	0.000713	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000193	0.000708	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—bone cancer	0.000193	0.000707	CcSEcCtD
Leflunomide—Urticaria—Epirubicin—bone cancer	0.000192	0.000704	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000191	0.0011	CbGpPWpGaD
Leflunomide—Pain—Doxorubicin—bone cancer	0.000191	0.000701	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—bone cancer	0.000191	0.000701	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—bone cancer	0.000191	0.000701	CcSEcCtD
Leflunomide—Body temperature increased—Epirubicin—bone cancer	0.000191	0.000701	CcSEcCtD
Leflunomide—Hypersensitivity—Methotrexate—bone cancer	0.00019	0.000698	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000188	0.00108	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NT5C3A—bone cancer	0.000188	0.00108	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000187	0.00108	CbGpPWpGaD
Leflunomide—Asthenia—Methotrexate—bone cancer	0.000185	0.000679	CcSEcCtD
Leflunomide—PTK2B—Immune System—ATF1—bone cancer	0.000185	0.00106	CbGpPWpGaD
Leflunomide—Feeling abnormal—Doxorubicin—bone cancer	0.000184	0.000676	CcSEcCtD
Leflunomide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000183	0.00067	CcSEcCtD
Leflunomide—Pruritus—Methotrexate—bone cancer	0.000183	0.00067	CcSEcCtD
Leflunomide—PTK2B—Immune System—IL3—bone cancer	0.00018	0.00103	CbGpPWpGaD
Leflunomide—Hypersensitivity—Epirubicin—bone cancer	0.000178	0.000653	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—bone cancer	0.000177	0.000651	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTGS2—bone cancer	0.000177	0.00102	CbGpPWpGaD
Leflunomide—Abdominal pain—Doxorubicin—bone cancer	0.000177	0.000648	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—bone cancer	0.000177	0.000648	CcSEcCtD
Leflunomide—Diarrhoea—Methotrexate—bone cancer	0.000177	0.000648	CcSEcCtD
Leflunomide—Asthenia—Epirubicin—bone cancer	0.000173	0.000636	CcSEcCtD
Leflunomide—Pruritus—Epirubicin—bone cancer	0.000171	0.000627	CcSEcCtD
Leflunomide—Dizziness—Methotrexate—bone cancer	0.000171	0.000626	CcSEcCtD
Leflunomide—Diarrhoea—Epirubicin—bone cancer	0.000165	0.000606	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—bone cancer	0.000165	0.000604	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—bone cancer	0.000164	0.000602	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000163	0.000939	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000163	0.000939	CbGpPWpGaD
Leflunomide—Rash—Methotrexate—bone cancer	0.000163	0.000597	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—bone cancer	0.000163	0.000596	CcSEcCtD
Leflunomide—Headache—Methotrexate—bone cancer	0.000162	0.000593	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000161	0.000926	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000161	0.000926	CbGpPWpGaD
Leflunomide—Asthenia—Doxorubicin—bone cancer	0.00016	0.000588	CcSEcCtD
Leflunomide—Dizziness—Epirubicin—bone cancer	0.00016	0.000586	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—bone cancer	0.000158	0.00058	CcSEcCtD
Leflunomide—Vomiting—Epirubicin—bone cancer	0.000154	0.000563	CcSEcCtD
Leflunomide—Nausea—Methotrexate—bone cancer	0.000153	0.000562	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—bone cancer	0.000153	0.000561	CcSEcCtD
Leflunomide—Rash—Epirubicin—bone cancer	0.000152	0.000559	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—bone cancer	0.000152	0.000558	CcSEcCtD
Leflunomide—Headache—Epirubicin—bone cancer	0.000151	0.000555	CcSEcCtD
Leflunomide—Dizziness—Doxorubicin—bone cancer	0.000148	0.000542	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000147	0.000847	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000147	0.000847	CbGpPWpGaD
Leflunomide—Nausea—Epirubicin—bone cancer	0.000143	0.000526	CcSEcCtD
Leflunomide—Vomiting—Doxorubicin—bone cancer	0.000142	0.000521	CcSEcCtD
Leflunomide—Rash—Doxorubicin—bone cancer	0.000141	0.000517	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—bone cancer	0.000141	0.000517	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SMO—bone cancer	0.00014	0.000807	CbGpPWpGaD
Leflunomide—Headache—Doxorubicin—bone cancer	0.00014	0.000514	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.00014	0.000803	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000138	0.000792	CbGpPWpGaD
Leflunomide—Nausea—Doxorubicin—bone cancer	0.000133	0.000487	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GNA11—bone cancer	0.000128	0.000738	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ATF1—bone cancer	0.000119	0.000686	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL3—bone cancer	0.000116	0.000669	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000115	0.000658	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KIT—bone cancer	0.000105	0.000604	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFBR2—bone cancer	9.95e-05	0.000572	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NDUFA12—bone cancer	9.79e-05	0.000563	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NT5C3A—bone cancer	9.49e-05	0.000545	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1R—bone cancer	9.37e-05	0.000538	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MDM2—bone cancer	8.27e-05	0.000475	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ENO2—bone cancer	8.23e-05	0.000473	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NT5C3A—bone cancer	8.11e-05	0.000466	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—DHFR—bone cancer	7.64e-05	0.000439	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—JUN—bone cancer	7.19e-05	0.000413	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNA11—bone cancer	7.14e-05	0.00041	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KIT—bone cancer	6.79e-05	0.00039	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP3A4—bone cancer	6.47e-05	0.000372	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BRAF—bone cancer	6.38e-05	0.000367	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—bone cancer	5.65e-05	0.000325	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTP1—bone cancer	5.53e-05	0.000318	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MDM2—bone cancer	5.35e-05	0.000307	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JUN—bone cancer	4.65e-05	0.000267	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—bone cancer	4.52e-05	0.00026	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ENO2—bone cancer	4.16e-05	0.000239	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—DHFR—bone cancer	3.86e-05	0.000222	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—bone cancer	3.66e-05	0.00021	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNA11—bone cancer	3.61e-05	0.000207	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENO2—bone cancer	3.55e-05	0.000204	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—DHFR—bone cancer	3.3e-05	0.000189	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP3A4—bone cancer	3.27e-05	0.000188	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.25e-05	0.000187	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNA11—bone cancer	3.08e-05	0.000177	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—bone cancer	3.07e-05	0.000176	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—bone cancer	2.87e-05	0.000165	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTP1—bone cancer	2.8e-05	0.000161	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP3A4—bone cancer	2.79e-05	0.000161	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.78e-05	0.00016	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTP1—bone cancer	2.39e-05	0.000137	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—bone cancer	1.45e-05	8.32e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—bone cancer	1.24e-05	7.11e-05	CbGpPWpGaD
